Insider · CIK 0001553335

Dupont Jakob

Reports to the SEC for 6 companies · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001553335

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-20	PYXSPyxis Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+46K sh	—	—	46,000
2026-06-30	PYXSPyxis Oncology, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−35K sh	—	—	357,461
2026-06-30	PYXSPyxis Oncology, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+35K sh	$1.60	+$56K	73,741
2026-06-30	PYXSPyxis Oncology, Inc.S Sale	Director	SSale	−35K sh	$3.06	−$107K	38,741
2026-06-10	BOLTBolt Biotherapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+5,000 sh	—	—	5,000
2026-03-24	PYXSPyxis Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+45.9K sh	—	—	45,867
2025-12-12	BOLTBolt Biotherapeutics, Inc. · Director Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−849 sh	—	—	0
2025-12-12	BOLTBolt Biotherapeutics, Inc. · Director Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−2,500 sh	—	—	0
2025-12-12	BOLTBolt Biotherapeutics, Inc. · Director Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−1,100 sh	—	—	0
2025-12-12	BOLTBolt Biotherapeutics, Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+1,100 sh	—	—	1,100
2025-12-12	BOLTBolt Biotherapeutics, Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+1,000 sh	—	—	1,000
2025-12-12	BOLTBolt Biotherapeutics, Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+849 sh	—	—	849
2025-12-12	BOLTBolt Biotherapeutics, Inc. · Director Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−1,000 sh	—	—	0
2025-12-12	BOLTBolt Biotherapeutics, Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+2,500 sh	—	—	2,500
2025-05-27	BOLTBolt Biotherapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+1,100 sh	—	—	1,100
2025-05-01	BOLTBolt Biotherapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2025-03-31	PYXSPyxis Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+37K sh	$0.98	+$36.2K	36,979
2024-09-03	BOLTBolt Biotherapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+17K sh	—	—	16,984
2024-09-03	BOLTBolt Biotherapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+50K sh	—	—	50,000
2024-03-26	PYXSPyxis Oncology, Inc.A Award	Director	AAward	+38.7K sh	—	—	38,741
2023-09-22	PYXSPyxis Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+392K sh	—	—	392,461
2023-08-23	Apexigen, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20.5K sh	—	—	0
2023-08-23	PYXSPyxis Oncology, Inc. · Stock Option (Right to buy)A Award	Director	AAward	+5,879 sh	—	—	5,879
2023-08-23	Apexigen, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−100K sh	—	—	0
2023-08-23	PYXSPyxis Oncology, Inc. · Stock Option (Right to buy)A Award	Director	AAward	+3,534 sh	—	—	3,534
2023-08-23	Apexigen, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−34.1K sh	—	—	0
2023-08-23	PYXSPyxis Oncology, Inc. · Stock Option (Right to buy)A Award	Director	AAward	+17.3K sh	—	—	17,250
2023-03-02	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, Head of R&D	SSale	−5,074 sh	$3.63	−$18.4K	290,794
2023-03-01	ATRAAtara Biotherapeutics, Inc.A Award	EVP, Head of R&D	AAward	+141K sh	—	—	295,868
2023-03-01	ATRAAtara Biotherapeutics, Inc. · Employee Stock Option (Right to Buy)A Award	EVP, Head of R&D	AAward	+318K sh	—	—	317,987
2022-11-16	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, Head of R&D	SSale	−1,124 sh	$4.49	−$5,047.884	154,540
2022-11-16	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, Head of R&D	SSale	−3,218 sh	$4.49	−$14.4K	155,664
2022-09-29	Apexigen, Inc.Stock Option (right to buy)A Award	Director	AAward	+100K sh	—	—	100,000
2022-08-16	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, Head of R&D	SSale	−4,124 sh	$5.03	−$20.8K	158,882
2022-05-17	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, Head of R&D	SSale	−3,873 sh	$5.32	−$20.6K	163,006
2022-03-01	ATRAAtara Biotherapeutics, Inc.A Award	EVP, Head of R&D	AAward	+78.5K sh	—	—	169,100
2022-03-01	ATRAAtara Biotherapeutics, Inc. · Employee Stock Option (Right to Buy)A Award	EVP, Head of R&D	AAward	+148K sh	—	—	147,573
2022-03-01	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, Head of R&D	SSale	−2,221 sh	$9.86	−$21.9K	166,879
2022-02-10	ATRAAtara Biotherapeutics, Inc. · Employee Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−5,000 sh	—	—	257,500
2022-02-10	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, Head of R&D	SSale	−5,000 sh	$16.00	−$80K	90,594
2022-02-10	ATRAAtara Biotherapeutics, Inc.M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+5,000 sh	$9.58	+$47.9K	95,594
2022-01-03	ATRAAtara Biotherapeutics, Inc.M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+5,000 sh	$9.58	+$47.9K	95,594
2022-01-03	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, Head of R&D	SSale	−5,000 sh	$16.01	−$80.1K	90,594
2022-01-03	ATRAAtara Biotherapeutics, Inc. · Employee Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−5,000 sh	—	—	262,500
2021-12-01	ATRAAtara Biotherapeutics, Inc.M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+5,000 sh	$9.58	+$47.9K	95,594
2021-12-01	ATRAAtara Biotherapeutics, Inc. · Employee Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−5,000 sh	—	—	267,500
2021-12-01	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, Head of R&D	SSale	−5,000 sh	$17.94	−$89.7K	90,594
2021-11-16	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, Head of R&D	SSale	−2,199 sh	$17.12	−$37.6K	90,594
2021-11-02	ATRAAtara Biotherapeutics, Inc.M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+5,000 sh	$9.58	+$47.9K	97,793
2021-11-02	ATRAAtara Biotherapeutics, Inc.S Sale	EVP, Head of R&D	SSale	−5,000 sh	$16.41	−$82.1K	92,793

Recent filings

Accepted (ET)
Aug 204
Dupont Jakob0001193125-26-359525
SEC(opens sec.gov)
Jul 24
Dupont Jakob0001193125-26-294708
SEC(opens sec.gov)
Jun 114
Dupont Jakob0001193125-26-267546
SEC(opens sec.gov)
Mar 254
Dupont Jakob0001193125-26-124388
SEC(opens sec.gov)
Dec 164
Dupont Jakob0001193125-25-321156
SEC(opens sec.gov)
Jul 24
Dupont Jakob0000950170-25-092941
SEC(opens sec.gov)
May 54
Dupont Jakob0000950170-25-063886
SEC(opens sec.gov)
Apr 24
Dupont Jakob0000950170-25-048898
SEC(opens sec.gov)
Sep 64
Dupont Jakob0001415889-24-023005
SEC(opens sec.gov)
Mar 284
Dupont Jakob0000950170-24-038102
SEC(opens sec.gov)

Companies

Address

C/O PYXIS ONCOLOGY, INC. 321 HARRISON AVENUE, 11TH FL. SUITE 1

BOSTON, MA, 02118